Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(8): 451-456
DOI: 10.1055/s-2005-865710
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Different Effects of Agonistic vs. Antagonistic GnRH-Analogues (Triptorelin vs. Cetrorelix) on Bone Modeling and Remodeling in Peripubertal Female Rats

C. L. Roth1 , C. Neu2 , H. Jarry3 , E. Schoenau2
  • 1Department of Pediatrics, University of Bonn, Germany
  • 2Children's Hospital, University of Cologne, Germany
  • 3Division of Clinical & Experimental Endocrinology, University of Göttingen, Germany
Further Information

Publication History

Received: March 12, 2005 First decision: April 10, 2005

Accepted: May 2, 2005

Publication Date:
08 September 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Little is known about the effects of antagonistic GnRH analogues vs. agonists on bone strength, specifically in context of treating precocious puberty. Peripubertal female rats were treated from postnatal day 25 - 36 with either the GnRH agonist triptorelin (TRIP) or the antagonist cetrorelix (CET). Using peripherial quantitative computerized tomography (pQCT) we investigated effects on bone parameters. Onset of puberty was retarded by both analogues as measured by prevention of vaginal opening at 36 d of age and reduced uterine weights. In the tibia, cortical content, cortical area related to body weight, and periosteal circumference related to weight were significantly reduced in CET-treated rats - indicating reduced bone modeling and reduced bone strength (cortical circumference related to body weight: CET 0.066 ± 0.001 vs. TRIP 0.068 ± 0.001 vs. controls 0.071 ± 0.001 mm/g, mean ± SEM, p < 0.05 CET vs. controls; cortical area related to body weight: CET 3.87 ± 0.46 vs. TRIP 6.80 ± 0.63 vs. controls 8.07 ± 1.13, × 10-3 mm2/g, p < 0.001 CET vs. controls; cortical content: CET 0.316 ± 0.038 vs. TRIP 0.546 ± 0.051 vs. controls 0.624 ± 0.089 mg/mm, p < 0.01 CET vs. controls). In conclusion, although both CET and TRIP inhibit puberty in rats, cortical thinning was only seen in CET-treated rats. This indicates that GnRH antagonist treatment might cause reduced bone strength which is partly comparable to postmenopausal bone loss. When using new GnRH antagonists for treating precocious puberty in humans, parameters for bone strength and mineralization should be monitored.

Key words

Puberty - GnRH-analogues - bone mineralization - bone modeling and remodeling

References

  • 1 Bakalov V K, Axelrod L, Baron J, Hanton L, Nelson L M, Reynolds J C, Hill S, Troendle J, Bondy C A. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency.  J Clin Endocrinol Metab. 2003;  88 5717-5722
    CrossrefPubMedGoogle Scholar
  • 2 Bertelloni S, Baroncelli G I, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.  Eur J Pediatr. 2000;  159 369-374
    CrossrefPubMedGoogle Scholar
  • 3 Comaru-Schally A M, Brannan W, Schally A V, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.  J Clin Endocrinol Metab. 1998;  83 3826-3831
    CrossrefPubMedGoogle Scholar
  • 4 Crowley Jr W F, Comite F, Vale W, Rivier J, Loriaux D L, Cutler Jr G B. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.  J Clin Endocrinol Metab. 1981;  52 370-372
    PubMedGoogle Scholar
  • 5 Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.  Cancer. 1998;  83 1561-1566
    CrossrefPubMedGoogle Scholar
  • 6 Frost H M, Schoenau E. The “muscle-bone unit” in children and adolescents: a 2000 overview.  J Pediatr Endocrinol Metab. 2000;  13 571-590
    CrossrefPubMedGoogle Scholar
  • 7 Griesinger G, Felberbaum R E, Schultze-Mosgau A, Diedrich K. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents?.  Drugs. 2004;  64 563-575
    PubMedGoogle Scholar
  • 8 Grumbach M M. Estrogen, bone, growth and sex: a sea change in conventional wisdom.  J Pediatr Endocrinol Metab. 2000;  13 (Suppl 6) 1439-1455
    PubMedGoogle Scholar
  • 9 Heger S, Partsch C J, Sippell W G. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.  J Clin Endocrinol Metab. 1999;  84 4583-4590
    CrossrefPubMedGoogle Scholar
  • 10 Horvath J E, Toller G L, Schally A V, Bajo A M, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.  Proc Natl Acad Sci USA. 2004;  101 4996-5001
    CrossrefPubMedGoogle Scholar
  • 11 Järvinen T L, Kannus P, Pajamaki I, Vuohelainen T, Tuukkanen J, Järvinen M, Sievanen H. Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading.  Bone. 2003;  32 642-651
    CrossrefPubMedGoogle Scholar
  • 12 Ke H Z, Foley G L, Simmons H A, Shen V, Thompson D D. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.  Endocrinology. 2004;  145 1996-2005
    PubMedGoogle Scholar
  • 13 Klein K O, Barnes K M, Jones J V, Feuillan P P, Cutler Jr G B. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.  J Clin Endocrinol Metab. 2001;  86 4711-4716
    CrossrefPubMedGoogle Scholar
  • 14 Lotinun S, Westerlind K C, Kennedy A M, Turner R T. Comparative effects of long-term continuous release of 16 alpha-hydroxyestrone and 17 beta-estradiol on bone, uterus, and serum cholesterol in ovariectomized adult rats.  Bone. 2003;  33 124-131
    CrossrefPubMedGoogle Scholar
  • 15 Mul D, Oostdijk W, Otten B J, Rouwe C, Jansen M, Delemarre-van de Waal H A, Waelkens J J, Drop S L. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience.  J Pediatr Endocrinol Metab. 2000;  13 (Suppl 1) 765-772
    PubMedGoogle Scholar
  • 16 Mul D, Bertelloni S, Carel J C, Saggese G, Chaussain J L, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.  Horm Res. 2002;  58 1-7
    PubMedGoogle Scholar
  • 17 Ojeda S R, Urbanski H F. Puberty in the rat:. The Physiology of Reproduction. 2nd ed. New York; Raven Press Ltd. 1994: 377-379
    Google Scholar
  • 18 Oostdijk W, Drop S L, Odink R J, Hummelink R, Partsch C J, Sippell W G. Long-term results with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.  Acta Paediatr Scand. 1991;  372 (Suppl) 39-45
    PubMedGoogle Scholar
  • 19 Ott S M. Attainment of peak bone mass.  J Clin Endocrinol Metab. 1990;  71 1082A-1082C
    PubMedGoogle Scholar
  • 20 Paoletti A M, Serra G G, Cagnacci A, Vacca A M, Guerriero S, Solla E, Melis G B. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.  Fertil Steril. 1996;  65 707-710
    PubMedGoogle Scholar
  • 21 Partsch C J, Heger S, Sippell W G. Management and outcome of central precocious puberty.  Clin Endocrinol (Oxf). 2002;  56 129-148
    CrossrefPubMedGoogle Scholar
  • 22 Rakover Y, Lu P, Briody J N, Tao C, Weiner E, Ederveen A G, Cowell C T, Ben-Shlomo I. Effects of delaying puberty on bone mineralization in female rats.  Hum Reprod. 2000;  15 1457-1461
    CrossrefPubMedGoogle Scholar
  • 23 Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally A M, Schally A V. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.  Hum Reprod. 1995;  10 1974-1981
    PubMedGoogle Scholar
  • 24 Reissmann T, Schally A V, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review.  Hum Reprod Update. 2000;  6 322-331
    CrossrefPubMedGoogle Scholar
  • 25 Roth C, Leonhardt S, Seidel C, Luft H, Wuttke W, Jarry H. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.  Pediatr Res. 2000;  48 468-474
    PubMedGoogle Scholar
  • 26 Roth C, Schricker M, Lakomek M, Strege A, Heiden I, Luft H, Munzel U, Wuttke W, Jarry H. Autoregulation of the GnRH system during puberty: effects of antagonistic versus agonistic GnRH analogues in a female rat model.  J Endocrinol. 2001;  169 361-371
    CrossrefPubMedGoogle Scholar
  • 27 Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty.  Expert Opin Investig Drugs. 2002;  11 1253-1259
    CrossrefPubMedGoogle Scholar
  • 28 Roth C, Hegemann F, Hildebrandt J, Balzer I, Witt A, Wuttke W, Jarry H. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.  Pediatr Res. 2004;  55 126-133
    PubMedGoogle Scholar
  • 29 Saggese G, Bertelloni S, Baroncelli G I, Battini R, Franchi G. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.  Eur J Pediatr. 1993;  152 717-720
    CrossrefPubMedGoogle Scholar
  • 30 Sagsveen M, Farmer J E, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.  Cochrane Database Syst Rev. 2003;  4 CD001297
    PubMedGoogle Scholar
  • 31 Schoenau E, Saggese G, Peter F, Baroncelli G I, Shaw N J, Crabtree N J, Zadik Z, Neu C M, Noordam C, Radetti G, Hochberg Z. From bone biology to bone analysis.  Horm Res. 2004;  61 257-269
    CrossrefPubMedGoogle Scholar
  • 32 Seeman E. Invited review: Pathogenesis of osteoporosis.  J Appl Physiol. 2003;  95 2142-2151
    CrossrefPubMedGoogle Scholar
  • 33 Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko P C, Bonjour J P. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects.  J Clin Endocrinol Metab. 1992;  75 1060-1065
    CrossrefPubMedGoogle Scholar
  • 34 Urbanski H F, Ojeda S R. In vitro simulation of prepubertal changes in pulsatile luteinizing hormone release enhances progesterone and 17 beta-estradiol secretion from immature rat ovaries.  Endocrinology. 1985;  117 638-643
    PubMedGoogle Scholar
  • 35 van der Eerden B C, Karperien M, Wit J M. The estrogen receptor in the growth plate: implications for pubertal growth.  J Pediatr Endocrinol Metab. 2001;  14 (Suppl 6) 1527-1533
    PubMedGoogle Scholar
  • 36 Wang L, McMahan C A, Banu J, Okafor M C, Kalu D N. Rodent model for investigating the effects of estrogen on bone and muscle relationship during growth.  Calcif Tissue Int. 2003;  72 151-155
    CrossrefPubMedGoogle Scholar
  • 37 Wildt L, Marshall G, Knobil E. Experimental induction of puberty in the infantile female rhesus monkey.  Science. 1980;  207 1373-1375
    CrossrefPubMedGoogle Scholar
  • 38 Yanovski J A, Rose S R, Municchi G, Pescovitz O H, Hill S C, Cassorla F G, Cutler Jr G B. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature.  N Engl J Med. 2003;  348 908-917
    CrossrefPubMedGoogle Scholar
  • 39 Zapatero-Caballero H, Sanchez-Franco F, Fernandez-Mendez C, Garcia-San Frutos M, Botella-Cubells L M, Fernandez-Vazquez G. Gonadotropin-releasing hormone receptor gene expression during pubertal development of female rats.  Biol Reprod. 2004;  70 348-355
    CrossrefPubMedGoogle Scholar

PD Dr. med. Christian L. Roth

Department of Pediatrics
University of Bonn

Adenauerallee 119

53113 Bonn

Email: croth@uni-bonn.de

      >